The Medicines Company (MDCO) PT Raised to $60 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
September 2, 2019 2:30 AM EDT-Â Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment
-Â ORION-11 study demonstrates inclisirans excellent safety profile, including no treatment-related liver or renal abnormalities
-Â Full study results presented during late-breaking science session at ESC Congress 2019
-Â The Medicines Company to host investor conference call and webcast on Monday, September 2, 2:00pm CET / 8:00am EDT
... More
